Key questions about cannabis and road safety remain unanswered as legalization expands
Despite growing evidence that cannabis increases crash risk, fundamental questions about dose-response relationships, tolerance effects, edible impairment timelines, and medical vs recreational user differences remain unresolved.
Quick Facts
What This Study Found
Cannabis contributes to crash risk, but key questions remain unanswered: the dose-response relationship is unclear, tolerance effects on driving are uncertain, different routes of administration (edibles, vaping) have different impairment timelines, and whether medical users are impaired differently from recreational users is unknown.
Key Numbers
Canada legalized non-medical cannabis October 2018; Uruguay in December 2013; evidence covers crash risk, impairment duration, and detection methods
How They Did This
Narrative review identifying and discussing key questions about cannabis and road safety, drawing on epidemiological, behavioral, and pharmacological evidence.
Why This Research Matters
Canada and other jurisdictions legalized cannabis with road safety as a central concern, but the evidence needed to inform effective impaired driving policies has significant gaps that urgently need filling.
The Bigger Picture
The cannabis-driving research gap is concerning because policies are being implemented based on incomplete evidence. Unlike alcohol, where the dose-response relationship with impairment is well-established, cannabis lacks equivalent scientific foundations for regulation.
What This Study Doesn't Tell Us
Many referenced studies use cannabis potencies lower than currently available products. Most driving research involves simulated rather than real-world driving. Sex differences in cannabis pharmacology and driving effects are understudied.
Questions This Raises
- ?Is there a reliable dose-response curve for cannabis and driving impairment?
- ?Should medical cannabis users face the same driving restrictions as recreational users?
- ?How do edibles affect driving compared to inhaled cannabis?
Trust & Context
- Key Stat:
- Dose-response relationship between cannabis and driving impairment remains unclear
- Evidence Grade:
- Narrative review synthesizing evidence across multiple research domains related to cannabis and road safety
- Study Age:
- Published in 2021, shortly after Canada became the second country to legalize non-medical cannabis.
- Original Title:
- Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues.
- Published In:
- Frontiers in psychiatry, 12, 641549 (2021)
- Authors:
- Brands, Bruna(9), Di Ciano, Patricia(10), Mann, Robert E(11)
- Database ID:
- RTHC-03023
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis impair driving?
Evidence shows cannabis contributes to crash risk, but key details like the dose-response relationship, how long impairment lasts, and how tolerance affects driving ability remain unclear.
Are medical cannabis users impaired when driving?
Whether medical users, who may develop tolerance, are impaired differently from recreational users is an important unanswered question. No definitive research has established this distinction.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-03023APA
Brands, Bruna; Di Ciano, Patricia; Mann, Robert E. (2021). Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues.. Frontiers in psychiatry, 12, 641549. https://doi.org/10.3389/fpsyt.2021.641549
MLA
Brands, Bruna, et al. "Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues.." Frontiers in psychiatry, 2021. https://doi.org/10.3389/fpsyt.2021.641549
RethinkTHC
RethinkTHC Research Database. "Cannabis, Impaired Driving, and Road Safety: An Overview of ..." RTHC-03023. Retrieved from https://rethinkthc.com/research/brands-2021-cannabis-impaired-driving-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.